Leaflet EVERTAS 4.6mg / 24h transdermal patch
- Product code:
- W60439006
- Quantity:
- 30
- Indicated for:
- Alzheimer's disease; dementia
- Route of administration:
- transdermal
- Substance:
- rivastigmine (cholinesterase inhibitor)
- ATC
- N06DA03 — Nervous system | Anti-dementia drugs | Anticholinesterases
Rivastigmine is a medication used for the symptomatic treatment of mild to moderate dementia associated with Alzheimer’s disease or Parkinson’s disease. It belongs to the class of cholinesterase inhibitors, working by increasing the levels of acetylcholine in the brain, a neurotransmitter essential for memory, learning, and thinking processes.
Rivastigmine is indicated to slow the progression of cognitive symptoms such as memory loss, difficulty concentrating, and reduced ability to perform daily activities. While it does not cure the disease, it can temporarily improve cognitive function and quality of life for patients.
The medication is available in the form of capsules, oral solution, or transdermal patches. The dose is gradually adjusted to minimize side effects, which may include nausea, vomiting, diarrhea, loss of appetite, and dizziness. Transdermal patches are often preferred to reduce the risk of gastrointestinal side effects.
Treatment with rivastigmine should be administered under the supervision of a doctor, and patients should be regularly monitored to assess efficacy and tolerability. Caregivers play an important role in ensuring proper administration and observing for any adverse effects.
Rivastigmine is indicated to slow the progression of cognitive symptoms such as memory loss, difficulty concentrating, and reduced ability to perform daily activities. While it does not cure the disease, it can temporarily improve cognitive function and quality of life for patients.
The medication is available in the form of capsules, oral solution, or transdermal patches. The dose is gradually adjusted to minimize side effects, which may include nausea, vomiting, diarrhea, loss of appetite, and dizziness. Transdermal patches are often preferred to reduce the risk of gastrointestinal side effects.
Treatment with rivastigmine should be administered under the supervision of a doctor, and patients should be regularly monitored to assess efficacy and tolerability. Caregivers play an important role in ensuring proper administration and observing for any adverse effects.
General data about EVERTAS 4.6mg / 24h
- Substance:
- rivastigmine
- Date of latest medicines list:
- 01-06-2026
- Product code:
- W60439006
- Concentration:
- 4.6mg / 24h
- Pharmaceutical form:
- transdermal patch
- Quantity:
- 30
- Product type:
- Generic medicine
- Price:
- 87.36 RON
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for rivastigmine
Concentrations available for rivastigmine
- 1.5mg
- 13.3mg/24h
- 2mg/ml
- 3.0mg
- 3mg
- 4.5mg
- 4.6mg/24h
- 6mg
- 9.5mg/24h